microbial iron chelators: a possible adjuncts for therapeutic treatment of sars-cov-2 like viruses

There is a need for targeted, effective antiviral therapeutic treatment for the global threat of covid-19, like viral pandemics. our efforts in this direction present the in-silico testing of a hypothesis through molecular docking. we have demonstrated the possibility of a microbial siderophore desferrioxamine-e produced by pseudomonas stutzeri sgm-1 for effective drug targeting and drug development against sars-cov-2, like viruses. iron homeostasis and covid-19 have a close relationship. an iron chelator desferrioxamine-e binding with the sars-cov-2 virus can inhibit the viral rna binding and packaging into the new virions inside the host cell. the well-known efficacy of iron chelation and rna binding domain of sars-cov-2 nucleocapsid interaction of desferrioxamine-e studied through molecular docking has promising potential for exploring microbial iron chelators as adjuncts for in-silico clinical trials and randomized clinical trials.